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Abstract Myasthenia gravis (MG) is caused by autoantibodies
to the acetylcholine receptor (AChR). Experiments with fetal
(K2LQN) and adult (K2LON) AChR and with recombinant subunit
dimers showed that some monoclonal antibodies (mAbs) against
the main immunogenic region (MIR), located on the K-subunit of
the AChR, bind better to fetal AChR and to KQ subunit dimer
than to adult AChR and KO dimer and equally to both KL and KN.
However, other anti-MIR mAbs prefer adult AChR and KO
dimer, bind well to KL but weakly to KN. These results suggest
that the MIR conformation is affected by the neighboring Q/O-
and N-subunits and may contribute to understanding the antibody
specificities in MG. ß 2000 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
The human muscle acetylcholine receptor (AChR) is a li-
gand-gated cation channel located on the postsynaptic mem-
brane of the neuromuscular junction. Its role is to transmit
the electric signal through the chemical synapse from the mo-
tor nerve terminal to the end-plate. It is a pentameric glyco-
protein that exists in the form of two subtypes, fetal and
adult. The fetal subtype (AChR-Q), with a stoichiometry
K2LQN, is found in fetal and denervated muscle, whereas the
adult subtype (AChR-O), with the composition K2LON, is
present at the end-plate in innervated adult muscle [1,2].
In myasthenia gravis (MG) and its experimental animal
model, autoantibodies target the muscle AChR [2^4]. Various
studies have shown that the majority of anti-AChR antibodies
in MG sera and experimental animals are directed against a
speci¢c region on each K-subunit of the AChR, termed the
main immunogenic region (MIR) [5^7].
The MIR, a small extracellular conformationally dependent
loop, contains a group of overlapping epitopes located at the
crest of each K-subunit within an AChR pentamer [3,7,8].
Although the MIR’s core epitope is believed to be K67-76
[9], there are other segments of the K-subunit, still unidenti-
¢ed, which possibly contribute to it [10,11]. The MIR is not
involved directly in channel function but plays a crucial path-
ogenetic role, since the anti-MIR antibodies are highly patho-
genic in experimental animals and responsible for most of the
antigenic modulation activity in sera from MG patients [12^
16].
In this study, we investigated whether the conformation of
the MIR is a¡ected by the subunits neighboring the two K-
subunits. Such a possibility could have serious immunological
implications since there are MG sera which di¡erentiate be-
tween embryonic and adult AChRs and bind better to one or
the other molecule [17^19]. The latter has been attributed to
the presence of antibodies that bind selectively to the Q- or the
O-subunit of the AChR. The generation of Q-subunit speci¢c
phage display fragments antibody binding derived from myas-
thenic patients with serum antibodies speci¢c for embryonic
AChR suggests that anti-Q-subunit antibodies do indeed exist
in these sera [20]. However, these ¢ndings do not exclude the
possibility that di¡erential binding results from conformation-
al alterations imposed on epitopes on K-, L- or c-subunits by
the Q- to O-subunit (fetal to adult) exchange. The latter might
be important for understanding neonatal MG and arthrogry-
posis congenital syndrome passively transferred by MG moth-
ers’ antibodies [21,22].
2. Materials and methods
AChR-Q and AChR-O were extracted from the TE671 and CN21
cell lines, respectively, as described earlier [11,19]. The subunit dimers
(KL, KQ, KN and KO) as well as the lone K-subunit were generated by
transient expression of the respective AChR subunit cDNAs in human
embryonic kidney (HEK) ¢broblast 293 cells. HEK293 cells were
plated out at 5U105/well on 6-well tissue culture plates. cDNAs en-
coding each of the human AChR subunits were cloned into the ex-
pression vector pcDNA3 (Invitrogen). Each well was transfected with
4 Wg of the respective AChR subunit cDNA combination using cal-
cium phosphate precipitation, as described previously [23]. Cells were
incubated for 48 h following transfection and then AChR subunit
combinations were extracted in 25 mM Tris^HCl (pH 7.5), 100 mM
NaCl, 1 mM EDTA, 1.25% Triton X-100, 1 mM PMSF. Subunit
dimerization in the extracts was veri¢ed by the e¡ective precipitation
of [125I]K-bungarotoxin-labeled KL, KQ and KN dimers using speci¢c
anti-L-(No. 73), anti-Q-(No. 67) and anti-N-(No. 137) subunit mono-
clonal antibodies (mAbs), respectively. The mAbs used were derived
earlier from rats immunized with intact AChR from several species;
some of their characteristics are shown in Table 1.
Radioimmunoassays (RIAs) with AChR-Q and AChR-O as well as
with the subunit dimers KL, KQ, KN and KO were carried out in prin-
ciple as described [24], with some modi¢cations. Brie£y, 200 Wl of
phosphate-bu¡ered saline, pH 7.5 (PBS)^0.5% Triton X-100 contain-
ing [125I]K-bungarotoxin-labeled AChR or recombinant subunit
dimers, su⁄cient to give approximately 5000 and 1000 cpm, respec-
tively, in the immunoprecipitates of the positive controls, were incu-
bated with 10 Wl of mAb diluted in PBS^0.2% bovine serum albumin
containing 0.1 Wl of normal rat serum, as carrier, for 2.5 h at 4‡C.
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Immune complexes were quantitatively precipitated by 10 Wl of rabbit
anti-rat immunoglobulin serum. After 1.5 h at 4‡C, the precipitates
were washed three times with PBS^0.5% Triton X-100 and bound
radioactivity was counted. Background radioactivity was determined
in the presence of the non-binding mAb 25, while an excess of mAb
192 was used as a positive control.
Statistical analysis was performed by the use of Student’s t test.
3. Results
The mAbs for this study were selected to have epitopes on
subunits common to both AChR subtypes, i.e. MIR and non-
MIR epitopes on the K-subunit and epitopes on the L-subunit.
The binding of these mAbs to AChR-Q, AChR-O as well as to
KQ, KO, KL and KN subunit dimers was estimated based on the
amount of [125I]K-bungarotoxin-labeled subtype or subunit
dimer combination immunoprecipitated (AChR bound in
Fig. 1 and subunit dimer bound in Fig. 2). Similar experi-
ments made using the K-subunit only showed that in the ab-
sence of other subunits, low cpm of the [125I]K-bungarotoxin-
labeled K-subunit could be precipitated (data not shown).
3.1. Binding of mAbs to fetal and adult AChRs
The left column in Fig. 1 shows that the mAbs 155 and 124
whose epitopes lie in the cytoplasmic domain of the K- and
L-subunits, respectively, bind equally well to both AChR sub-
types. Similar results are seen for the anti-MIR mAb 203.
mAb 203 is representative of another six anti-MIR mAbs
(No. 35, 190, 192, 195, 202 and 204), which also bound
equally well to both AChR-Q and AChR-O. In all cases, the
di¡erence in the binding of the above mAbs to the two
AChRs did not exceed the 11% of the total binding. However,
¢ve anti-MIR mAbs (No. 198, 42, 37, 65 and 207) were found
able to discriminate between the two forms of the AChR.
Speci¢cally, mAbs in the middle column of Fig. 1 (No. 198,
37 and 42) bound better to AChR-O than AChR-Q, whereas
Table 1
Characteristics of anti-AChR mAbs used












37 K67-76, MIR AChR-O/KO
42 K67-76, MIR AChR-O/NTc
198 K67-76, MIR AChR-O/KO
65 K, MIR AChR-Q/KQ
207 K, MIR AChR-Q/KQ
155 K371-378, cytoplasmic
73 L, near MIR
124 L354-359, cytoplasmic
67 Q, near MIR
137 N374-391
a[9,11,25^27].
bFrom the present results.
cNot tested.
Fig. 1. Comparison of mAb binding to AChR-Q (squares) and AChR-O (triangles) using RIAs. mAbs in the ¢rst column (No. 203, 124 and
155) show no discrimination between the two AChR subtypes. mAbs in the second column (No. 198, 42 and 37) bind better to AChR-O (di¡er-
ences statistically signi¢cant, P6 0.05, except in mAb 37 for 0.05 Wl), whereas mAbs in the last column (No. 65 and 207) bind better to
AChR-Q (di¡erences statistically signi¢cant, P6 0.05). Values shown are mean þ S.D., n = 3.
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the converse was true for mAbs 65 and 207 (right column of
Fig. 1).
3.2. Binding of mAbs to KQ, KO, KL and KN subunit dimers
To further con¢rm the observed di¡erences and to study
the possible e¡ect of other AChR subunits besides the Q- or
O-subunits, the mAbs presented above were tested using re-
combinant KQ, KO, KL and KN subunit dimers. Fig. 2 shows
that mAbs 198 and 37 bound better to KO subunit dimer than
to KQ, whereas mAbs 65 and 207 bound better to KQ subunit
dimer (di¡erences statistically signi¢cant, P6 0.05), in agree-
ment with their preference to AChR-O and AChR-Q, respec-
tively, as presented in Fig. 1. Although the di¡erences in the
mAb binding to KQ and KO subunit dimers were rather mod-
erate at high antibody concentration, especially for mAbs 198
and 207, they were quite signi¢cant for small mAb concen-
trations.
As far as KL and KN subunit dimers are concerned, Fig. 2
also shows that mAb 203, which bound equally to both
AChR subtypes, bound similarly to KL and KN subunit
dimers. Likewise, mAbs 207 and 65, which preferred AChR-
Q and KQ dimer, bound equally to both KL and KN subunit
dimers, though less than to KQ. However, mAbs 198 and 37,
which bound better to AChR-O and KO dimer, bound consid-
erably weakly to KN subunit dimer although they bound well
to KL. The possibility that the good binding of all anti-MIR
mAbs to KL dimer was due to free K-subunit in the extract
was excluded by the use of an anti-L-subunit mAb (No. 73)
which could precipitate practically all (96%) of the [125I]K-
bungarotoxin-labeled K-subunit.
4. Discussion
The MIR of mammalian muscle and Torpedo electric organ
AChRs is known to be located on the K-subunits of the
AChR [3,9,11,25]. However, we present here anti-MIR
mAbs that have di¡erential binding and thus discriminate
between the fetal and the adult AChR’s MIR. This latter
suggests either that the conformation of the MIR in the two
subtypes is not identical or that the neighboring subunits par-
ticipate in the MIR epitopes. Since the di¡erence between fetal
and adult AChR is the substitution of an O-subunit for a Q,
then it is these subunits that either contribute to the MIR
epitope or are responsible for the altered MIR conformation.
The recombinant subunit dimer experiments veri¢ed the
above conclusion and further suggested that in addition to
the Q/O-subunits, the N-subunit, too, a¡ects the MIR confor-
mation. On the other hand, although these experiments do not
reveal any e¡ect of the L-subunit on the conformation of the
epitopes for the mAbs used in this study, a possible involve-
ment of the L-subunit in determining the MIR conformation
cannot be excluded.
The observation that the L-subunit does not a¡ect the bind-
ing of the anti-MIR mAbs used in this study, yet binding to
KL dimer is relatively high, strongly suggests that non-K-sub-
units do not directly participate in the MIR and therefore the
variations in mAb binding to the other dimers are due to
conformational alterations imposed to the MIR by the Q-, O-
or N-subunits.
Table 1 shows that the two groups of anti-MIR mAbs
(AChR-O/KO and AChR-Q/KQ preferring mAbs) di¡er in their
speci¢city for the K67-76 synthetic peptide: the AChR-O/KO
preferring mAbs bind to the K67-76 peptide, whereas the
AChR-Q/KQ preferring mAbs do not bind to any synthetic
peptide. This di¡erentiation may imply small di¡erences in
the actual epitopes of the two groups of mAbs. On the other
hand, those mAbs which do not discriminate between the two
AChR subtypes bind either to K67-76 or to unidenti¢ed epi-
topes.
4.1. Immunological implications
Several MG sera are found to bind preferentially to the
fetal or the adult AChR subtype [17^19] and this di¡erentia-
tion seems to play an important role in the development of
MG symptoms in the adults, where antibodies binding pref-
erentially to adult AChR should be the most potent, as well as
Fig. 2. Comparison of mAb binding to KQ (squares), KO (triangles), KL (circles) and KN (diamonds) subunit dimers using RIAs. mAbs in the
second column (No. 198 and 37) bind better to KO dimer in comparison with KQ but although they bind well to KL dimer, they bind more
weakly to KN. mAbs in the last column (No. 65 and 207) bind better to KQ than to KO and equally to KL and KN dimers. Values shown are
mean, n = 3.
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in the development of neonatal MG and anti-AChR-mediated
congenital arthrogryposis [21,22], in which antibodies binding
preferentially to the embryonic form of the AChR should be
most potent. The results we present imply that di¡erences in
the binding of MG patient’s anti-AChR antibodies to fetal or
adult AChR may not only be due to di¡erential binding to the
Q- or the O-subunits but also to an altered conformation of the
MIR (and possibly of other epitopes) on the two AChR sub-
types.
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